25th Jan 2006 07:28
Hikma Pharmaceuticals Plc25 January 2006 25 January 2006 Hikma Announces FDA Approval of Saudi Arabian Manufacturing Facility for the Production of Oral Cephalosporin Products Hikma Pharmaceuticals PLC (LSE: HIK), the multinational pharmaceuticals group,today announced that the US FDA has approved its Abbreviated New DrugApplication (ANDA) filings for the oral cephalosporin, Cephalexin in 250mg and500 mg capsule form. These products will be manufactured by JazeeraPharmaceutical Industries (JPI), Hikma's 47.5 per cent. owned associate companyin Riyadh, Saudi Arabia, for sale in the US market. JPI has received US FDAapproval for the manufacture of oral Cephalosporin products. JPI is the first company in the Gulf area with FDA approved facilities and allof Hikma's major manufacturing sites in the US, Jordan, Portugal and SaudiArabia are now FDA approved. - ENDS - Enquiries: Hikma Pharmaceuticals plc Bassam Kanaan, Chief Financial Officer +962 6 580 2900Susan Ringdal, Investor Relations Director +44 20 7479 4893 Brunswick Group Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed +44 207404 5959 Notes to Editors About HikmaHikma Pharmaceuticals plc (LSE: HIK) is a multinational pharmaceutical groupfocused on developing, manufacturing and marketing a broad range of both brandedand non-branded generic and in-licensed pharmaceutical products. Hikma'soperations are conducted through three businesses: Generic, Branded andInjectable Pharmaceuticals. Hikma's operations are based principally in theUnited States, the Middle East and North Africa ("MENA") Region, and Europe. TheCompany had net sales of $214m in 2004 and had approximately 1730 employees asat 30 September 2005. About JPIHikma's associate company in Saudi Arabia, JPI, has a 15,100 square metrefacility in Riyadh. This facility has the capacity to manufacture 500 milliontablets, 150 million capsules, 30 million bottles, 20 million suppositories, aswell as two million tubes of ointments. JPI's facility has been certified by theSaudi Arabian Ministry of Health and the State Institute for Drug control inSlovakia, and is FDA approved. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals